Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
Reads0
Chats0
TLDR
The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.Abstract:
Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR 16 ) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD 17 ]) defined remission; a QIDS-SR 16 total score of ≥11 (HRSD 17 ≥14) defined relapse. Results: The QIDS-SR 16 remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, t...read more
Citations
More filters
Journal ArticleDOI
Depression and Coronary Heart Disease
TL;DR: There are exciting findings in the field of depression and coronary heart disease, and randomized controlled trials of depression treatment are beginning to delineate the types of depression management strategies that may benefit the many coronaryHeart disease patients with depression.
Journal ArticleDOI
A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
TL;DR: In a simulated trial 100,000 subjects in a current episode of major depressive disorder received citalopram or bupropion based on the clinician's decision or following indications from 5-HTTLPR genetic testing, this simulation is favourable to incorporate pharmacogenetic test in antidepressant treatment.
Journal ArticleDOI
Deciphering sex differences in the immune system and depression.
TL;DR: The relationship between depression and the immune system from a sex-based perspective is explored and hormonal and genetic sex specific immune mechanisms that may contribute to the etiology of mood disorders are proposed.
Journal ArticleDOI
Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial.
TL;DR: Ketamine, a rapidly acting antidepressant with antisuicidal properties, might offer relief in depressed patients presenting to emergency departments with acute suicidal ideation.
Journal ArticleDOI
The impact from the aftermath of chronic stress on hippocampal structure and function: Is there a recovery?
J. Bryce Ortiz,Cheryl D. Conrad +1 more
TL;DR: The current understanding of how a chronically stressed hippocampus improves after a post-stress rest period is discussed, which is a critical next step in understanding how to promote resilience in the face of stressors.
References
More filters
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
A. John Rush,Madhukar H. Trivedi,Hicham M. Ibrahim,Thomas J. Carmody,Bruce A. Arnow,Daniel N. Klein,John C. Markowitz,Philip T. Ninan,Susan G. Kornstein,Rachel Manber,Michael E. Thase,James H. Kocsis,Martin B. Keller +12 more
TL;DR: The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings.
Journal ArticleDOI
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries: Results from the IQOLA Project
Barbara Gandek,John E. Ware,Neil K. Aaronson,Giovanni Apolone,Jakob B. Bjorner,John Brazier,Monika Bullinger,Stein Kaasa,Alain Leplège,Luis Prieto,Marianne Sullivan +10 more
TL;DR: In this article, the authors compared the SF-12 and SF-36 summary measures in nine European countries (Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom).
Journal ArticleDOI
Cumulative illness rating scale.
TL;DR: A Cumulative Illness Rating Scale, designed to meet the need for a brief, comprehensive and reliable instrument for assessing physical impairment, has been developed and tested and is well suited to a variety of research uses.
Journal ArticleDOI
The Inventory of Depressive Symptomatology (IDS): Psychometric properties.
TL;DR: Analysis of sensitivity to change in symptom severity in an open-label trial of fluoxetine showed that the IDs-C and IDS-SR were highly related to the 17-item Hamilton Rating Scale for Depression.